Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P778: Microbial characterization of paediatric inflammatory bowel disease and stratification into disease severity groupsECCO '17 Barcelona
Year: 2017
Authors:

Olbjørn C.*1,2, Cvancarova Småstuen M.3, Casén C.4, Nakstad B.1,2, Lindahl T.4, Rove J.B.1, Thiis-Evensen E.5, Vatn M.H.6, Perminow G.7

1Akershus University Hospital, Pediatric and Adolescent Medicine, Lørenskog, Norway 2University of Oslo, Institute of Clinical Medicine, Campus Ahus, Oslo, Norway 3Oslo and Akershus University College of Applied Sciences, Faculty of Health Sciences, Oslo, Norway 4Genetic Analysis AS, Oslo, Norway 5Oslo University Hospital, Department of Gastroenterology, Rikshospitalet, Oslo, Norway 6University of Oslo, Epigen Institute, Institute of Clinical Medicine, Campus Ahus, Oslo, Norway 7Oslo University Hospital, Department of Pediatrics, Ullevål, Oslo, Norway

P779: CD patients in deep remission harbor a high dysbiosis index similar to active CD at diagnosis, yet both are higher in comparison to healthy controlsECCO '17 Barcelona
Year: 2017
Authors:

Haberman Y.*1,2, Klein T.1, Di Segni A.1, Neuman S.1, Levhar N.1, Bubis M.1, Picard O.1, BenShoshan M.1, Farage Barhom S.1, Glick Saar E.1, Cesarkas K.1, Lahad A.1, Shouval D.1, Weiss B.1, Eliakim R.1, Ben-Horin S.1, Kopylov U.1 Israeli IBD Research Nucleus (IIRN)

1Sheba Medical Center, Tel Hashomer, Israel 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States

P780: 3-oxo-C12:2-HSL, a new N-acyl-homoserine lactone identified in gut ecosystem exerts an anti-inflammatory effect and does not modify paracellular permeabilityECCO '17 Barcelona
Year: 2017
Authors:

Le Balc'h E.*1, Landman C.1, Tauziet E.1, Brot L.1, Quevrain E.1, Rainteau D.1, Grill J.-P.1, Thenet S.2, Seksik P.1

1APHP St. Antoine Hospital, ERL U1157/UMR 7203, Paris, France 2Centre de Recherche des Cordeliers, UMR S 1138, Paris, France

P781: The stability of the fecal microbiota in Crohn's disease patients with changing disease courseECCO '17 Barcelona
Year: 2017
Authors:

Tedjo D.1,2, Savelkoul P.2, Masclee A.1, Bodelier A.1, Pierik M.1, Penders J.2, Jonkers D.*1

1School of Nutrition and Translational Research in Metabolism (NUTRIM), Division Gastroenterology-Hepatology, Maastricht University Medical Center+, Maastricht, Netherlands 2School of Nutrition and Translational Research in Metabolism (NUTRIM), Department of Medical Microbiology, Maastricht University Medical Center+, Maastricht, Netherlands

P782: A new compatibility test for donor selection for faecal microbiota transplantation in ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Ponce-Alonso M.1, Garcia-Fernandez S.1, Aguilera L.2, Rodriguez-de-Santiago E.2, Foruny J.R.2, Roy G.3, DelCampo R.1, Canton R.1, Lopez-Sanroman A.*2

1Hospital Ramon y Cajal, Department of Microbiology, Madrid, Spain 2Hospital Ramon y Cajal, Department of Gastroenterology & Hepatology, Madrid, Spain 3Hospital Ramon y Cajal, Department of Immunology, Madrid, Spain

P783: Ciprofloxacin resistance in ESBL producing enterobacteriaceae colonizing the gut in IBD patientsECCO '17 Barcelona
Year: 2017
Authors:

Skuja V.*1,2, Pekarska K.3, Straume Z.2,4, Rudzīte D.5, Lavrinoviča E.5, Piekuse L.6, Dauvarte H.3, Vašuka E.1,7, Dobelniece L.1,7, Zalizko P.4,8, Derovs A.2,9, Krūmiņa A.10,11, Lejnieks A.1,7

1Riga Stradins University, Department of Internal Medicine, Riga, Latvia 2Riga East Clinical University Hospital, Gastroenterology, Hepatology and Nutrition Clinic, Riga, Latvia 3Riga Stradins University, Faculty of Medicine, Riga, Latvia 4University of Latvia, Department of Gastroenterology, Riga, Latvia 5Riga East Clinical University Hospital, Laboratory Medicine Centre, Department of Microbiology, Riga, Latvia 6Riga Stradins University, Scientific Laboratory of Molecular Genetics, Riga, Latvia 7Riga East Clinical University Hospital, Department of Internal Medicine, Riga, Latvia 8Pauls Stradins Clinical University Hospital, Department of Gastroenterology, Hepatology and Nutrition, Riga, Latvia 9Riga Stradins University, Department of Gastroenterology, Riga, Latvia 10Riga Stradins University, Department of Infectious diseases, Riga, Latvia 11Riga East Clinical University Hospital, Department of Infectious Diseases, Riga, Latvia

P784: A comparison study of the mucosa-associated microbiota between inflamed and non-inflamed sites in ulcerative colitis patientsECCO '17 Barcelona
Year: 2017
Authors:

Hirano A.*1, Umeno J.1, Shibata H.2, Kitazono T.1, Esaki M.1

1Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan 2Kyushu University, Medical Institute of Bioregulation, Fukuoka, Japan

P785: Association of Bacteroidetes with endoscopic activity in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Baston I.*1, Sueiro R.2, Uribarri L.1, Ferreiro R.1, Leiro J.M.2, Dominguez-Munoz J.E.1, Barreiro-de Acosta M.1

1University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain 2University of Santiago de Compostela, Department of Microbiology and Parasitology, Institute of Food Research and Analysis, Santiago, Spain

P786: Correlation between the presence of Bacteroidetes and faecal calprotectin for the detection of endoscopic activity in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Baston I.*1, Sueiro R.2, Ferreiro R.1, Uribarri L.1, Leiro J.M.2, Dominguez-Munoz J.E.1, Barreiro-de Acosta M.1

1University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain 2University of Santiago de Compostela, Department of Microbiology and Parasitology, Institute of Food Research and Analysis, Santiago, Spain

P787: The microbiota and it's role in anti-TNF therapy non-responseECCO '17 Barcelona
Year: 2017
Authors:

Ding N.S.*1,2,3, Perdones-Montero A.4, Sarafian M.3,5, Rees D.4, Penez L.5, Holmes E.3, Marchesi J.3, Hart A.3,5

1St Vincent's Hospital, Inflammatory Bowel Disease, Melbourne, Australia 2St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom 3Imperial College London, Department of Surgery and Cancer, London, United Kingdom 4Imperial College, Surgery and Cancer, London, United Kingdom 5St Mark's Hospital, IBD, London, United Kingdom

P788: Microbiota related disease activity and distribution in subgroups of inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Ricanek P.*1, Rahul K.2, Ber Y.3, Vatn S.1,4, Finnby L.5, Lindahl T.5, Bergemalm D.6, Carsten A.6, Söderholm J.7, Jahnsen J.1,4, Gomollon F.3, Halfvarson J.6, Satsangi J.2, Casen C.5, Vatn M.H.1,4 IBD-Character Consortium, University of Edinburgh, Edinburgh, United Kingdom

1Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway 2University of Edinburgh, Edinburgh, United Kingdom 3Hospital Clinico Universitario, Zaragoza, Spain 4University of Oslo, Institute of Clinical Medicine, Oslo, Norway 5Genetic Analysis AS, Oslo, Norway 6Örebro University, Faculty of Medicine and Health, Örebro, Sweden 7Linköping University, Linköping, Sweden

P789: Microbiome composition is altered in patients with IBD independent of endoscopic activityECCO '17 Barcelona
Year: 2017
Authors:

Boland K., Turpin W., Mohammadi A., Borowski K., Smith M.I., Nguyen G., Steinhart A.H., Croitoru K., Silverberg M.

Mount Sinai Hospital, Zane Cohen Center for Digestive Diseases, Toronto, Canada

P790: Microbiota profile in pediatric IBD: correlations with phenotype and disease activityECCO '17 Barcelona
Year: 2017
Authors:

Gatti S., Annibali R., Del Baldo G., Franceschini E., Lionetti E., Albano V., Galeazzi T., Catassi C.

Università Politecnica delle Marche, Department of Pediatrics, Ancona, Italy

P791: Activation of the aryl hydrocarbon receptor after simvastatin and recombinant antagonist of receptors of interleukin-1 treatment in a rat model of inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Kamyshnyi A., Kamyshna V., Kozachuk A.

Zaporozhye State Medical University, Zaporozhye, Ukraine

P792: Modulation of the fecal metagenome in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Rojas-Feria M.*1, Fernández Caballero-Rico J.A.2, Pastor Ramírez H.3, Castro-Fernandez M.1, Chueca Porcuna N.2, Grande Santamaría L.1, Romero-Gόmez M.3, García F.2, Del Campo J.A.1

1Valme Hospital, UGC Digestive Disease, Seville, Spain 2Complejo Hospitalario Universitario de Granada, Microbiology, Granada, Spain 3Institute of Biomedicine of Seville, UG IC Digestive Diseases Virgen Macarena-Virgen Rocío, Seville, Spain

P793: Microbial composition in IBD may influence clinical symptoms independent of endoscopic activityECCO '17 Barcelona
Year: 2017
Authors:

Boland K., Turpin W., Mohammadi A., Borowski K., Kabakchiev B., Smith M.I., Nguyen G., Steinhart A.H., Croitoru K., Silverberg M.

Mount Sinai Hospital, Zane Cohen Center for Digestive Diseases, Toronto, Canada

P794: Alterations of intestinal microbiota in ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Danilova N.1, Abdulkhakov S.1,2, Grigoryeva T.*2, Dubinkina V.3, Odintsova V.4, Tyakht A.3,4, Pavlenko A.4, Odintsova A.2, Abdulkhakov R.1, Govorun V.4

1Kazan State Medical University, Kazan, Russian Federation 2Kazan Federal University, Kazan, Russian Federation 3Moscow Institute of Physics and Technology, Moscow, Russian Federation 4Federal Research Centre of Physical-Chemical Medicine, Moscow, Russian Federation

DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohn’s disease patientsECCO '16 Amsterdam
Year: 2016
Authors:

K. M. Taylor*1, 2, N.S. Taylor3, S. H. Anderson1, P. M. Irving1, N. J. Prescott2, C. M. Lewis2, C. G. Mathew2, J. D. Sanderson1

1Guy’s & St Thomas’ NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, 2King’s College London, Department of Medical & Molecular Genetics, London, United Kingdom, 3University Hospital Southampton NHS Foundation Trust, Department of Gastroenterology, Southampton, United Kingdom

DOP002: Molecular response to ustekinumab in moderate-to-severe Crohn’s disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studiesECCO '16 Amsterdam
Year: 2016
Authors:

K. Li*, K. Hayden, E. Wadman, S. Bhagat, S. Emrich, J. R. Friedman, C. Gasink, C. Brodmerkel

Janssen R & D, LLC, Spring House, Pennsylvania, United States

DOP003: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

K. Li*1, J. Ouahed2, J. Friedman1, R. Strauss1, D. Chan1, S. Telesco1, D. Shouval3, J. Canavan4, C. Brodmerkel1, S. Snapper5

1Janssen R & D, LLC, Spring House, Pennsylvania, United States, 2Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, United States, 3Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, United States, 4Harvard Medical School/Brigham & Women’s Hospital, Boston, Massachusetts, United States, 5Boston Children’s Hospital/Harvard Medical School/Brigham & Women’s Hospital, Boston, Massachusetts United States